Optimizing Outpatient Care: Clinical Strategies for Managing Hepatic Encephalopathy in Primary Practice - Episode 7
Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
Published on:
Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
- Which agents do we have to target abnormalities in gut-liver axis to prevent and treat HE? (lactulose or lactitol, rifaximin) Sanchez-Delgado et al 2016
- What is the mechanism of action of these therapies?
- What is their tolerability and their side effect profile?
